Please login to the form below

Not currently logged in
Email:
Password:

GSK agrees to co-promote Auxilium’s Testim in US

US biopharma Auxilium raises financial guidance for year based on deal for its testosterone gel brand

Auxilium's Testim testosterone gel

GlaxoSmithKline (GSK) has agreed a co-promotion deal with Auxilium Pharmaceuticals to exclusively market the testosterone gel Testim in the US.

Based on the news, Auxilium raised its estimated 2012 revenues from between $283m and $305m to between $293 and $315m.

The US biopharma now expects a maximum net loss of $10m rather the $15m it had previously expected.

GSK's sales reps are anticipated to begin promoting Testim, which is indicated for testosterone replacement therapy in adult males with a lack of testosterone, as early as the third quarter of 2012.

Auxilium will remain responsible for manufacturing Testim, as well as all regulatory activities.

The agreement is based on a minimum revenue forecast for the product up to September 30, 2015, which will have to be reached before GSK is compensated.

In addition, Auxilium will pay GSK specified tail payments following the term of the agreement if certain conditions are met.

Adrian Adams, president and CEO of Auxilium, explained that the “strength and breadth” of GSK's commercial operations in the US would allow more physicians to have access to the product, boosting sales.

In a statement, GSK said that Testim will complement the company's existing portfolio of cardiovascular, metabolic and urology products, with its sales force already having links with physicians regarding testosterone replacement therapy.

Cheryl MacDiarmid, VP of GSK's cardiovascular/metabolic/urology business, said: "Urology remains one of GSK's key therapeutic areas, and our sales professionals are well positioned to provide physicians with information on the treatment of hypogonadism.”

Insufficient secretion of testerone leads to low levels of the hormone in men, with symptoms including impotence, fatigue and mood depression.

The Testim gel contains one per cent of the same testosterone hormone as produced in the human body, and helps return testosterone to normal levels when absorbed into the bloodstream through the skin.

According to analysts IMS, sales of testosterone gels in the US comprised $1.4bn during 2011.

22nd May 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics